Amgen and Samsung Bioepis can continue to sell their Soliris (eculizumab) biosimilars in Europe, after the Court of Appeal of the Unified Patent Court refused originator Alexion’s request for injunctions. Alexion had sought injunctive relief based on its European patent 3,167,888,B1 covering the treatment of paroxysmal nocturnal hemoglobinuria.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?